Page 180 - Programme book for The International Liver Congress 2015, EASL ILC 2015
P. 180
Liver Tumours: Clinical (Epidemiology, Diagnosis) (Cont.)

P0347 CORRELATION OF VARIOUS METABOLIC PARAMETERS
OF 18F-FDG PET WITH HISTOLOGIC FEATURES AND
RECURRENCE OF HCC
Yang-Hyon Baek*, Sang-Young Han, Sung-Lee Lee,Young-Jin Jeong,
Young-Jin Jeong, Jin-Sook Jeong, South Korea

P0348 CAN HISTOLOGIC GRADE BE PREDICTED IN
HEPATOCELLULAR CARCINOMA PATIENTS USING
ENHANCEMENT DEGREE OF GD-EOB-DTPA-ENHANCED
MAGNETIC RESONANCE IMAGES?; A PROSPECTIVE
COHORT STUDY
Young-Joo Jin*, Soon Gu Cho, Joon Mee Kim, Jin-Woo Lee, South Korea

P0349 SFRP-4, A POTENTIAL NOVEL SERUM MARKER FOR
HEPATITIS B VIRUS-RELATED HEPATOCELLULAR
CARCINOMA
Cheng Xu, Xianghua Zeng,Yuming Wang*, China 

P0350 KOREAN VERSION OF A MODEL TO ESTIMATE SURVIVAL
IN AMBULATORY PATIENTS WITH HEPATOCELLULAR
ePOSTERS CARCINOMA (K-MESIAH)
Byung Ho Nam, Joong-Won Park*, Sook-Hyang Jeong, Sang Soo Lee,
Ami Yu, Bo Hyun Kim, W R. Kim, South Korea

YI P0351 HIGHLY SENSITIVE A-FETOPROTEIN, LENS CULINARIS
AGGLUTININ-REACTIVE FRACTION OF A-FETOPROTEIN
AND DES-Ɣ-CARBOXY PROTHROMBIN FOR
HEPATOCELLULAR CARCINOMA DETECTION IN AN
ITALIAN COHORT

Maria Lorena Abate, Gian Paolo Caviglia*, Elisa Petrini, Silvia Gaia,
Patrizia Carucci, Antonina Smedile, Italy

P0352 NEUTROPHIL LYMPHOCYTE RATIO (NLR) AT DIAGNOSIS
IS A PREDICTOR FOR SURVIVAL IN PATIENTS RECEIVING
SORAFENIB FOR ADVANCED HEPATOCELLULAR
CARCINOMA (HCC): A LARGE UK COHORT
Mehran Afshar*, Helen Clarke, Abigail Jackson-Wilding, Ali Ahmed,
Yuk Ting Ma, Pankaj Punia, The United Kingdom

P0353 PROTEIN BIOMARKERS REACTIVEWITH HCC SERA SERVE AS
A SIGNATURE FOR HEPATOCELLULAR CARCINOMA (HCC)
Nancy S Reau*, Marc Bissonnette, Sara Forrester, Daniel Schabacker,
Timothy Barder, Donald Jensen, The United States

180 The International Liver Congress™ 2015 • ILC Programme
   175   176   177   178   179   180   181   182   183   184   185